- Home
- »
- Biotechnology
- »
-
Transfection Reagents And Equipment Market Report, 2033GVR Report cover
Transfection Reagents And Equipment Market (2026 - 2033)
Size, Share & Trends Analysis Report By Product (Reagents, Equipment), By Method (Electroporation, Liposomes), By Application, By End-use, By Region, And Segment Forecasts
Market Size, 2025
$1.6BMarket Estimate, 2026
$1.7BMarket Forecast, 2033
$3.1BCAGR, 2026–2033
8.9%Transfection Reagents And Equipment Market Summary
The global transfection reagents and equipment market size was valued at USD 1.6 billion in 2025 and is projected to grow from USD 1.7 billion in 2026 to USD 3.1 billion by 2033, growing at a CAGR of 8.9% from 2026 to 2033. North America dominated the global market with the largest revenue share of 38.2% in 2025.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- By product: Reagent segment held the largest revenue share of 53.1% in 2025.
- By method: Electroporation segment held the largest revenue share of 22.2% in 2025.
- By application: Gene expression studies segment held the largest revenue share of 22.6% in 2025.
- By end use: Pharmaceutical and biotechnology companies segment held the largest revenue share of 54.9% in 2025.
Regional Highlights
- Largest regional market: North America (38.2% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025
Market Size & Forecast
- Market size in 2025: USD 1.6 Billion
- Estimated market size in 2026: USD 1.7 Billion
- Projected market size by 2033: USD 3.1 Billion
- CAGR (2026-2033): 8.9%
Three ways to get this report
Buy it, customize it, or ask a question.Ask an Analyst
Analyst response in 1 business day
- AccessReport author, directly
- Reply timeWithin 1 working day
- No sales callDirect answer only
- FormatEmail reply
- CostFree, no cost
Get the Full Report
What the study covers
- FormatsPDF · Excel · Dashboard
- Timeline2026–2033 annual, 2025 base
- Coverage20+ countries, 5 regions
- Companies10+ key players profiled
Customize the Report
20% free customization
- IncludeCountries, segments, points
- TailorTo your product definition
- ExtendDeeper competitor detail
- OrA fully bespoke study
- Turnaround5–10 working days
To learn more about this report, Download Free Sample Report Market Dynamics
The ongoing development and commercialization of gene and cell therapies are major market drivers. Transfection technologies are fundamental to the delivery of DNA, RNA, mRNA, plasmids, and gene-editing constructs into target cells during research, preclinical development, and manufacturing. As pharmaceutical and biotechnology companies increasingly focus on curative therapies for genetic disorders, cancer, and rare diseases, demand for efficient transfection solutions continues to rise. The success of gene therapies relies heavily on reliable transfection systems that support vector production, cell engineering, and therapeutic development.
The expansion of the clinical pipeline demonstrates this growing need. According to the International Society for Cell & Gene Therapy (ISCT) Global Regulatory Report 2025, there were 322 active cell and gene therapy clinical programs in the global pipeline, with most concentrated in Phase I and Phase II development. The report also noted that genetically modified cell therapies represented 53% of all clinical trials, highlighting the increasing use of gene transfer and cell-engineering technologies that depend on transfection reagents and instruments.
Regulatory approvals are further accelerating demand. In June 2024, the U.S. Food and Drug Administration (FDA) expanded approval of Elevidys, a gene therapy for Duchenne muscular dystrophy, making it available to a broader patient population. The approval reflects the increasing acceptance of gene-based treatments and encourages additional investment in gene therapy pipelines. As more therapies advance toward commercialization, manufacturers require large-scale transfection technologies for viral vector production and cell modification processes.
The continuous expansion of biopharmaceutical and biotechnology research and development (R&D) activities is a significant market driver. Transfection technologies play a critical role in drug discovery, recombinant protein production, monoclonal antibody development, vaccine research, cell-line engineering, and functional genomics studies. As biopharmaceutical companies intensify efforts to develop innovative biologics, gene therapies, and precision medicines, the demand for reliable transfection reagents and advanced transfection instruments continues to increase across both research and manufacturing environments.
A key indicator of this trend is the sustained growth in global pharmaceutical R&D investment. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the global pharmaceutical industry invested approximately USD 298 billion in R&D in 2023, representing one of the highest levels of research spending ever recorded. The increasing allocation of resources toward biologics, cell therapies, and molecular medicine directly supports the adoption of transfection technologies used for gene expression, target validation, and therapeutic development.
The rapid expansion of CRISPR and other gene-editing technologies has emerged as a significant market driver. Gene-editing platforms such as CRISPR-Cas9, CRISPR-Cas12, TALENs, and zinc finger nucleases require efficient delivery of nucleic acids, guide RNAs, and gene-editing complexes into target cells. Transfection reagents and electroporation systems play a critical role in enabling these processes, making them indispensable tools in genetic engineering, therapeutic development, functional genomics, and disease modeling applications.
The growing clinical adoption of CRISPR-based therapies highlights the increasing demand for transfection technologies. In December 2023, the U.S. Food and Drug Administration (FDA) approved CASGEVY (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, as the world's first CRISPR-based gene-editing therapy for sickle cell disease. The therapy involves ex vivo editing of patients' hematopoietic stem cells before reinfusion, a process heavily dependent on advanced transfection and cell-engineering techniques. The landmark approval validated the commercial potential of gene-editing technologies and accelerated investment in research programs utilizing transfection platforms.
Research activity in the gene-editing sector continues to expand rapidly. According to the American Society of Gene & Cell Therapy (ASGCT), the global pipeline included more than 4,000 gene, cell, and RNA therapy programs under development in 2024, many of which incorporate CRISPR and other genome-editing approaches. The increasing number of preclinical and clinical-stage programs requires extensive use of transfection reagents for guide RNA delivery, plasmid transfection, gene knockout studies, and cell-line engineering. This expanding development pipeline is creating sustained demand for high-efficiency transfection technologies across academic institutions and biopharmaceutical companies.
Investment in CRISPR research is also increasing globally. In October 2024, the Wellcome Trust announced a commitment of up to GBP 10 million to support advanced genome-editing research initiatives focused on improving the safety and effectiveness of CRISPR technologies. Similar investments from government agencies, academic institutions, and biotechnology companies are accelerating research into inherited disorders, oncology, infectious diseases, and regenerative medicine. As researchers seek higher editing efficiencies and improved cellular delivery methods, demand for innovative transfection reagents and electroporation equipment continues to grow.
Market Concentration & Characteristics
The transfection reagents and equipment industry is characterized by rapid technological advancements, increasing demand for efficient gene delivery systems, and expanding applications in cell and gene therapy, vaccine development, and functional genomics. The market comprises chemical, lipid-based, polymer-based, and electroporation technologies designed to deliver nucleic acids into mammalian and non-mammalian cells with high efficiency and minimal cytotoxicity. Growing investments in biotechnology research, CRISPR gene editing, RNA therapeutics, and personalized medicine are driving product innovation and adoption. The market is highly competitive, with companies focusing on reagent optimization, automation, and scalable transfection platforms for research and clinical manufacturing. In addition, increasing collaboration among biotechnology firms, academic institutions, and pharmaceutical companies continues to accelerate innovation and commercialization opportunities worldwide.
The transfection reagents and equipment industry demonstrates a high degree of innovation, driven by advances in non-viral gene delivery technologies, lipid nanoparticle formulations, electroporation systems, and automated transfection platforms. Continuous R&D efforts are improving transfection efficiency, cell viability, and scalability for research and therapeutic applications. Integration with CRISPR, RNA-based therapeutics, and cell and gene therapy workflows, along with AI-enabled optimization and high-throughput screening, is further accelerating technological innovation and market growth.
To learn more about this report, Download Free Sample Report The transfection reagents and equipment industry is witnessing a moderate to high level of mergers and acquisitions (M&A) as leading life science companies strengthen their portfolios in gene delivery and cell therapy technologies. Acquisitions are primarily focused on expanding reagent capabilities, electroporation platforms, and proprietary transfection technologies. Strategic partnerships with biotechnology firms and research organizations are also increasing, enabling companies to enhance innovation, broaden product offerings, and expand their global market presence.
Regulations have a moderate to high impact on the transfection reagents and equipment industry, particularly for products intended for clinical and therapeutic applications. Manufacturers must comply with Good Manufacturing Practices (GMP), quality management standards, and regulatory requirements established by agencies such as the FDA, EMA, and other national authorities. While stringent regulations increase development timelines and costs, they also ensure product safety, quality, and clinical reliability, fostering greater market confidence.
Product expansion in the transfection reagents and equipment industry is driven by increasing demand for high-efficiency, low-toxicity, and application-specific transfection solutions. Companies are launching advanced lipid-based reagents, polymer-based systems, electroporation devices, and automated platforms compatible with CRISPR, RNA therapeutics, and cell- and gene-therapy workflows. Continuous product innovation focuses on improving transfection efficiency, scalability, and reproducibility while addressing diverse research, bioprocessing, and clinical manufacturing requirements.
Regional expansion is accelerating as companies strengthen their presence across North America, Europe, and Asia-Pacific, where investments in biotechnology, pharmaceutical R&D, and cell and gene therapy continue to grow. Emerging markets, particularly China, India, South Korea, and Singapore, are attracting significant investments due to expanding research infrastructure and supportive government initiatives. Companies are establishing regional manufacturing facilities, distribution partnerships, and R&D collaborations to improve accessibility and capture emerging growth opportunities.
Analyst perspective
The Transfection Reagents & Equipment Market is positioned for sustained growth, driven by expanding applications in cell and gene therapy, mRNA therapeutics, CRISPR-based genome editing, and advanced biologics research. Demand is shifting toward high-efficiency, low-toxicity transfection platforms that support both laboratory research and scalable manufacturing. Automation, closed-system processing, and reagent optimization are improving reproducibility while reducing workflow complexity. Pharmaceutical and biotechnology companies continue to increase investments in genetic engineering and personalized medicine, creating long-term opportunities for technology providers. However, cost constraints, variable transfection efficiency across cell types, and regulatory requirements remain key considerations influencing broader market adoption and commercialization.
Product Insights
The reagent segment dominated the transfection reagents and equipment market and accounted for the largest revenue share of 53.1% in 2025. This dominance can be attributed to the large number of product launches by key players aimed at expanding their transfection reagent portfolios. Beyond the routine use of reagents and kits across experimental workflows, the availability of cost-effective, high-efficiency reagents continues to drive segment growth. For instance, in October 2024, Thermo Fisher Scientific expanded its transfection portfolio with next-generation lipid-based transfection reagents designed to improve gene delivery efficiency for mRNA and CRISPR applications. Similarly, in March 2024, Polyplus introduced advanced GMP-grade transfection reagents to support large-scale viral vector manufacturing for cell and gene therapy applications.
The equipment segment is anticipated to grow at the fastest CAGR over the forecast period. This growth is driven by the development of advanced cell systems and electroporation platforms that enable simple, cost-effective transient transfection while maintaining high performance and compatibility with primary cells. These systems are increasingly adopted for biotherapeutic production and drug discovery. For instance, in June 2024, Lonza expanded its Nucleofector platform with enhanced automation capabilities to improve transfection efficiency and throughput for cell therapy manufacturing. In addition, Bio-Rad Laboratories introduced upgraded electroporation solutions to support scalable gene-editing and cell-engineering workflows, further accelerating equipment adoption across research and biopharmaceutical laboratories.
Method Insights
The electroporation segment dominated the market, accounting for 22.2% of revenue in 2025. Wide portfolios of electroporation solutions offered by established and emerging players are boosting segment growth. Moreover, it is effective for the delivery of various nucleic acids, including DNA, RNA, and siRNA[SN4.1], which allows researchers to conduct a wide array of experiments, including gene expression studies, gene knockout experiments, and functional genomics studies, which further contribute to segment growth.
However, the liposomes segment is projected to experience the fastest growth rate over the forecast period. The ability to encapsulate and protect nucleic acids from degradation during the transfection process makes them a reliable choice for various experimental applications, such as gene expression studies, drug delivery, and gene therapy. Furthermore, liposomes [SN5.1] are known for their safety and low cytotoxicity compared with some other transfection methods, thereby contributing to segment growth.
Application Insights
The gene expression studies segment dominated the market, accounting for 22.6% of revenue in 2025. This is owing to the expansion of the genomic data pool and the rising emphasis on translating genomic information into clinical workflows. In addition, segment expansion is expected to be boosted by the numerous ongoing studies that concentrate on gene expression for the detection of chromosomal abnormalities.
The biomedical research segment is projected to witness the fastest growth rate over the forecast period. The demand for transcription reagents and equipment in biomedical research is driven by the ongoing advancement of molecular biology and genomics. Researchers in fields such as cancer biology, neuroscience, immunology, and regenerative medicine rely heavily on transcription techniques to investigate the role of specific genes, proteins, and signaling pathways in various diseases and conditions.
End Use Insights
The pharmaceutical and biotechnology companies segment accounted for a substantial share of the transfection reagents & equipment market, driven by the extensive use of transfection technologies across drug discovery, biologics development, cell and gene therapy programs, target validation, process development, and commercial research activities. These organizations utilize transfection platforms to introduce nucleic acids into cells for evaluating gene function, engineering cellular models, producing recombinant proteins, and assess therapeutic candidates. As pharmaceutical and biotechnology companies continue to expand their investments in precision medicine, advanced biologics, and next-generation therapeutics, transfection technologies have become essential tools that support research, development, and preclinical workflows. The growing complexity of therapeutic pipelines and increasing focus on innovative treatment modalities continue to generate strong demand for transfection reagents, consumables, and associated instrumentation.
To learn more about this report, Download Free Sample Report The academic and research institutes segment is projected to witness the fastest growth rate over the forecast period, driven by the extensive utilization of transfection technologies across universities, government laboratories, research hospitals, and non-profit research organizations. These institutions rely on transfection tools to support basic research, translational studies, scientific discovery, and educational activities aimed at advancing the understanding of cellular and molecular processes. Transfection technologies play a critical role in enabling gene function analysis, pathway characterization, disease mechanism investigations, and experimental model development, making them indispensable components of modern life science research. The continuous expansion of scientific research programs and academic initiatives worldwide continues to support strong demand for transfection reagents, consumables, and associated equipment.
Regional Insights
North America dominated the transfection reagents and equipment market, accounting for a 38.2% revenue share in 2025, supported by its advanced biotechnology ecosystem, strong concentration of biopharmaceutical innovators, and extensive cell and gene therapy development activities. The region serves as a major hub for viral vector manufacturing, gene editing, and engineered cell therapy research, all of which depend on efficient nucleic acid delivery technologies. Rising investments in precision medicine, regenerative therapies, and advanced biologics production continue to accelerate demand for transfection reagents, electroporation systems, and associated consumables. In addition, the presence of established life sciences companies, robust research funding, and sophisticated manufacturing infrastructure facilitates the rapid adoption of next-generation transfection technologies. These advantages have positioned North America as a key revenue-generating region within the global market.
To learn more about this report, Download Free Sample Report U.S. Transfection Reagents And Equipment Market Trends
The transfection reagents and equipment market in the U.S. is experiencing significant growth, supported by the country's leadership in biotechnology innovation, advanced therapeutic research, and biopharmaceutical manufacturing. The country hosts a dense network of pharmaceutical companies, biotechnology firms, academic institutions, and contract development organizations that extensively utilize transfection technologies in gene editing, protein expression, cell engineering, and viral vector production. Growing investments in cell and gene therapies, mRNA-based therapeutics, and precision medicine continue to expand the adoption of transfection reagents and electroporation systems across research and commercial applications. Furthermore, the presence of major industry participants, strong research funding, and a mature commercialization ecosystem accelerates the development and deployment of advanced gene delivery technologies. These factors collectively position the U.S. as the leading contributor to the global market.
Europe Transfection Reagents And Equipment Market Trends
The transfection reagents and equipment market in Europe is expanding, supported by its strong biotechnology sector, extensive academic research network, and well-established biopharmaceutical manufacturing base. The region remains at the forefront of cell and gene therapy development, gene editing research, and advanced biologics production, creating sustained demand for efficient gene delivery technologies. The presence of leading pharmaceutical companies, specialized research institutes, and contract development and manufacturing organizations continues to drive the adoption of transfection reagents, electroporation systems, and related consumables in both research and commercial environments.
The UK transfection reagents and equipment marketis expanding. The country remains a key center for cell and gene therapy development, gene-editing research, and advanced biologics innovation, driving sustained demand for transfection reagents, electroporation systems, and other gene-delivery technologies. The presence of leading academic institutions, biotechnology companies, and advanced therapy developers continues to support technology adoption across both research and translational applications. In addition, ongoing investments in life sciences innovation and therapeutic development are reinforcing the market's growth trajectory and strengthening the UK's position within the European market.
The transfection reagents and equipment market in Germanyis supported by the country's strong biotechnology sector, advanced biopharmaceutical manufacturing capabilities, and extensive research infrastructure. Germany serves as a key hub for gene editing, cell engineering, and advanced therapeutic development activities, creating sustained demand for transfection reagents, electroporation systems, and related gene delivery technologies. The presence of leading life sciences companies, research institutes, and biopharmaceutical manufacturers continues to drive the adoption of advanced transfection solutions across both research and commercial applications. These factors have established Germany as one of the most important markets for transfection technologies within Europe.
Asia Pacific Transfection Reagents And Equipment Market Trends
The transfection reagents and equipment market in the Asia Pacific is one of the fastest-growing, supported by expanding biotechnology research activities, increasing investment in advanced therapeutics, and growing biopharmaceutical manufacturing capabilities. The region is witnessing substantial progress in gene editing, cell engineering, regenerative medicine, and nucleic acid-based therapeutic development, all of which depend on efficient gene delivery technologies. Rising government support for life sciences innovation, increasing research funding, and the expansion of biotechnology infrastructure continue to drive demand for transfection reagents, electroporation systems, and associated consumables across research and commercial applications. These factors are strengthening the Asia Pacific's position as a major growth hub within the global market.
China transfection reagents and equipment market is supported by the country's rapidly expanding biotechnology industry, growing biopharmaceutical manufacturing capabilities, and increasing investment in advanced therapeutic development. China has emerged as a major center for gene editing, cell engineering, nucleic acid therapeutics, and biologics research, driving substantial demand for transfection reagents, electroporation systems, and related gene delivery technologies. The presence of a large number of biotechnology companies, research institutions, and biopharmaceutical manufacturers continues to accelerate the adoption of advanced transfection solutions across both research and commercial applications. These factors have positioned China as one of the largest and fastest-growing markets for transfection technologies in the Asia-Pacific region.
The transfection reagents and equipment market in Japanis supported by the country's leadership in regenerative medicine, advanced therapeutic research, and biotechnology innovation. Japan maintains a strong ecosystem of pharmaceutical companies, biotechnology firms, academic institutions, and research organizations actively engaged in gene editing, cell engineering, stem cell research, and nucleic acid-based therapeutic development. Growing investments in regenerative medicine, advanced biologics, and precision medicine continue to drive demand for high-performance transfection reagents, electroporation systems, and specialized gene delivery technologies. These factors have positioned Japan as one of the leading markets for transfection technologies within the Asia Pacific region.
Latin America Transfection Reagents And Equipment Market Trends
The transfection reagents and equipment market in Latin America is emerging, supported by expanding biotechnology research activities, increasing investment in biopharmaceutical development, and growing interest in advanced therapeutic technologies. Research institutions, biotechnology companies, and pharmaceutical manufacturers across the region are increasingly using transfection technologies in molecular biology research, gene expression studies, cell engineering, and biologics development. Government initiatives supporting biotechnology innovation and expanding life sciences infrastructure are further contributing to market growth across key countries, including Brazil, Mexico, Argentina, and Chile.
Brazil transfection reagents and equipment market is supported by the country's well-established biotechnology sector, expanding biomedical research ecosystem, and growing investment in biopharmaceutical innovation. Academic institutions, research organizations, biotechnology companies, and public health research centers are increasingly utilizing transfection technologies across gene expression studies, cell engineering, vaccine development, gene editing, and biologics research applications. Government initiatives supporting biotechnology advancement and the expansion of life sciences infrastructure continue to drive demand for transfection reagents, electroporation systems, and specialized gene delivery technologies. These factors have positioned Brazil as the largest market for transfection technologies within Latin America.
Middle East & Africa Transfection Reagents And Equipment Market Trends
The transfection reagents and equipment market in MEA is supported by growing investments in biotechnology research, expanding life sciences infrastructure, and increasing focus on genomics and advanced therapeutic development. Research institutions, academic centers, healthcare organizations, and biotechnology companies across the region are increasingly utilizing transfection technologies in molecular biology research, gene expression studies, cell engineering, and biologics development applications. Government-led initiatives aimed at strengthening biotechnology capabilities and promoting scientific innovation are further supporting demand for transfection reagents, electroporation systems, and specialized gene delivery technologies. These developments continue to enhance the region's role within the global life sciences landscape.
Saudi Arabia transfection reagents and equipment market is supported by the country's growing biotechnology sector, expanding life sciences infrastructure, and increasing investment in genomics, precision medicine, and advanced therapeutic research. Research institutions, healthcare organizations, and biotechnology companies are increasingly using transfection technologies in molecular biology research, gene expression studies, cell engineering, and biologics development. Government initiatives under Vision 2030 aimed at strengthening biotechnology innovation and developing a knowledge-based economy continue to drive demand for transfection reagents, electroporation systems, and specialized gene delivery technologies. These factors are positioning Saudi Arabia as one of the leading biotechnology markets within the Middle East.
Key Transfection Reagents And Equipment Company Insights
Key market players are adopting market strategies, such as new product launches, collaborations, and geographical expansions, to increase their global footprint. For instance, in January 2025, BIPEA introduced a new proficiency test in surface microbiology, expanding its offerings. This new test allows professionals in the field to enhance their expertise and proficiency in surface microbiology analysis.
Key Transfection Reagents And Equipment Companies
The following key companies have been profiled for this study on the transfection reagents and equipment market:
-
Thermo Fisher Scientific, Inc.
-
Promega Corporation
-
Lonza
-
QIAGEN
-
F. Hoffmann-La Roche Ltd.
-
Bio-Rad Laboratories Inc.
-
Merck KGaA
-
OriGene Technologies Inc.
-
MaxCyte, Inc.
-
POLYPLUS TRANSFECTION
-
Horizon Discovery Ltd.
-
PromoCell GmbH.
Competitive Benchmarking
Operating Strategies
Competitive Edge
Weaknesses
Mature Players: Thermo Fisher Scientific
- Focus on expanding transfection reagent portfolios, developing high-efficiency lipid-based and polymer-based reagents, enhancing electroporation technologies, strengthening GMP manufacturing capabilities, and forming strategic collaborations with cell & gene therapy developers, CDMOs, and research institutions to accelerate commercial adoption.
- Benefit from broad product portfolios, strong global distribution networks, established customer relationships, extensive R&D investments, regulatory expertise, and integrated life science solutions, enabling rapid commercialization and sustained leadership across research and therapeutic applications.
- Face challenges related to premium product pricing, increasing competition from specialized transfection technology providers, lengthy product validation processes, and the need for continuous investment in next-generation delivery technologies to maintain market leadership.
Emerging Players: Mirus Bio
- Concentrate on developing application-specific transfection reagents, novel non-viral delivery technologies, customized gene delivery platforms, and innovative formulations for CRISPR, mRNA, and cell therapy applications while leveraging strategic partnerships and academic collaborations for market expansion.
- Possess greater flexibility in technology innovation, faster product development cycles, specialized expertise in niche applications, and the ability to deliver customized solutions with improved transfection efficiency and lower cytotoxicity, creating strong differentiation in emerging therapeutic markets.
- Operate with relatively limited commercial infrastructure, lower global brand recognition, constrained financial resources, and dependence on partnerships for manufacturing, regulatory approvals, and international expansion, which may limit large-scale market penetration.
Recent Development
-
In February 2026, MaxCyte launched the ExPERT DTx, a high-throughput electroporation platform designed for transfection, gene editing, and cell engineering workflows.
-
In November 2025, the ProteanFect TuffCell Transfection Kit was introduced, a non-viral, non-liposomal transfection system offering high-efficiency nucleic acid delivery with low cytotoxicity in primary and difficult-to-transfect cells.
-
In October 2025, Lonza expanded its cell and gene therapy portfolio with TheraPEAK 293-GT Medium, a chemically defined medium optimized for AAV production in HEK293 cells and compatible with commonly used transfection reagents.
Transfection Reagents And Equipment Market Report Scope
Report Attribute
Details
Market size in 2025
USD 1.6 billion
Estimated market size in 2026
USD 1.7 billion
Projected market size by 2033
USD 3.1 billion
Growth rate
CAGR of 8.9% from 2026 to 2033
Historical data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Product, method, application, end use region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; Thailand; South Korea; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Thermo Fisher Scientific Inc.; Promega Corporation; Lonza; QIAGEN; F. Hoffmann-La Roche Ltd.; Bio-Rad Laboratories, Inc.; Merck KGaA; OriGene Technologies, Inc.; MaxCyte; Polyplus
Customization scope
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Transfection Reagents And Equipment Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global transfection reagents and equipment market report based on product, application, method, end use, and region:
-
Product Scope Outlook (Revenue, USD Billion, 2021 - 2033)
-
Reagents
-
Equipment
-
-
Method Scope Outlook (Revenue, USD Billion, 2021 - 2033)
-
Electroporation
-
Liposomes
-
Particle Bombardment
-
Microinjection
-
Adenoviral Vectors
-
Calcium Phosphate
-
DEAE-dextran
-
Magnetic Beads
-
Activated Dendrimers
-
Laserfection
-
-
Application Outlook (Revenue, USD Billion, 2021 - 2033)
-
Gene Expression Studies
-
Protein Production
-
Transgenic Models
-
Therapeutic Delivery
-
Cancer Research
-
Biomedical Research
-
-
End Use Outlook (Revenue, USD Billion, 2021 - 2033)
-
Academic And Research Institutes
-
Pharmaceutical And Biotechnology Companies
-
-
Regional Scope Outlook (Revenue, USD Billion, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
Thailand
-
South Korea
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The transfection reagents and equipment market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each transfection reagents and equipment segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Product
Revenue capture definition
Reagents
Revenue is primarily captured through the sale of chemical, lipid-based, polymer-based, peptide-based, and biological formulations that enable nucleic acid delivery into cells across research, drug discovery, and therapeutic development workflows.
Equipment
Revenue flows from the commercialization of transfection instruments, electroporation systems, microinjection platforms, laser-based devices, accessories, software, installation, and maintenance supporting efficient intracellular delivery of genetic material.
Segment - Method
Revenue capture definition
Electroporation
Market value is derived from electroporation instruments, proprietary consumables, disposable cuvettes, electrodes, protocol software, and service contracts used for electrically mediated nucleic acid delivery into cells.
Liposomes
Revenue originates from lipid-based transfection reagents, optimized lipid formulations, proprietary kits, and supporting consumables designed for efficient DNA, RNA, and mRNA delivery into diverse cell types.
Particle Bombardment
Revenue streams arise from gene gun systems, microprojectile cartridges, coated particles, launch consumables, and maintenance solutions used for direct intracellular nucleic acid delivery, particularly in plant and specialized research.
Microinjection
Market demand translates into sales of microinjection workstations, precision manipulators, injection needles, imaging integration, and accessories enabling direct nucleic acid delivery into individual cells or embryos.
Adenoviral Vectors
Commercial value is captured through adenoviral vector production services, viral transfection kits, vector optimization technologies, custom manufacturing, and supporting quality-control solutions for research and therapeutic applications.
Calcium Phosphate
Revenue is obtained from calcium phosphate transfection kits, prepared buffers, formulation reagents, laboratory consumables, and protocol optimization products supporting economical nucleic acid delivery in research laboratories.
DEAE-dextran
Revenue is supported by sales of DEAE-dextran transfection reagents, laboratory-grade formulations, optimized preparation kits, and associated consumables for transient gene expression studies in compatible cell models.
Magnetic Beads
Revenue flows from magnetic nanoparticle transfection kits, magnetic separation devices, specialized magnets, consumables, and workflow solutions enabling magnet-assisted intracellular nucleic acid delivery.
Activated Dendrimers
Commercial returns stem from dendrimer-based transfection reagents, customized polymer formulations, specialized delivery kits, and supporting consumables developed for high-efficiency, low-toxicity gene transfer applications.
Laserfection
Market value is generated through laser-assisted transfection platforms, optical modules, disposable accessories, software integration, and maintenance services supporting targeted intracellular nucleic acid delivery.
Segment Application
Revenue capture definition
Gene Expression Studies
Revenue is primarily captured through recurring demand for transfection reagents, instruments, assay kits, and workflow consumables supporting temporary or stable gene expression analysis in research laboratories.
Protein Production
Revenue flows from products enabling recombinant protein expression, including transfection reagents, scalable delivery systems, production-grade consumables, and equipment supporting laboratory and bioprocess applications.
Transgenic Models
Market value is driven by transfection technologies, embryo manipulation systems, gene delivery reagents, and specialized consumables used for creating genetically modified cellular and animal research models.
Therapeutic Delivery
Revenue originates from clinical-grade transfection platforms, GMP-compliant reagents, scalable delivery equipment, process optimization technologies, and manufacturing support for cell and gene therapy development.
Cancer Research
Commercial demand supports spending on advanced transfection reagents, delivery platforms, assay consumables, and laboratory systems used for oncology target validation, biomarker studies, and functional genomic research.
Biomedical Research
Revenue is captured through broad utilization of transfection reagents, instruments, consumables, and supporting technologies across molecular biology, immunology, neuroscience, regenerative medicine, and other life science research fields.
Segment End-use
Revenue capture definition
Academic and Research Institutes
Revenue is primarily captured through institutional procurement of transfection reagents, laboratory equipment, consumables, maintenance services, and research-grade solutions supporting basic and translational scientific investigations.
Pharmaceutical and Biotechnology Companies
Revenue flows from enterprise-scale purchases of high-performance transfection platforms, GMP-compatible reagents, automated equipment, process development solutions, and long-term service agreements supporting drug discovery and biopharmaceutical manufacturing.
Estimation Model
The Transfection Reagents & Equipment Market size was estimated using a bottom-up methodology by identifying leading manufacturers, benchmarking their transfection product portfolios, and assessing product-level sales across reagents, equipment, and transfection technologies. Technology-wise revenues were validated using adoption rates and end-user utilization, aggregated, and further verified through market share analysis of key companies to derive the overall market size.
To learn more about this report, Download Free Sample Report Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Transfection Reagents & Equipment Market Opportunity and Commercialization Strategy Assessment
Developed a comprehensive assessment of the global transfection reagents and equipment market, evaluating market size, growth opportunities, competitive landscape, technology advancements, regulatory environment, end-user demand, and commercialization strategies across research, biopharmaceutical, cell & gene therapy, and vaccine development applications.
Enables life science companies, reagent manufacturers, instrument developers, and investors to identify high-growth market segments, optimize commercialization strategies, prioritize geographic expansion, and capitalize on opportunities in cell and gene therapy, functional genomics, and precision medicine.
Cell & Gene Therapy and Transfection Technology Adoption Analysis
Delivered an in-depth analysis of transfection technology adoption across academic research, biopharmaceutical R&D, CDMOs, and clinical manufacturing, including reagent and instrument utilization, technology preferences (lipid-based, electroporation, viral/non-viral), workflow integration, application trends, and emerging therapeutic opportunities.
Provides actionable insights to improve market access strategies, strengthen product positioning, identify unmet workflow challenges, and align product development with evolving cell & gene therapy, RNA therapeutics, genome editing, and vaccine research requirements.
Frequently Asked Questions About This Report
Some key players operating in the transfection reagents & equipment market include Thermo Fisher Scientific Inc.; Promega Corporation; QIAGEN; Mirus Bio LLC; Merck KGaA; and Bio-Rad Laboratories, Inc.
Key factors that are driving the transfection reagents & equipment market growth include ongoing R&D in cancer management, implementation of favorable government initiatives & external funding for R&D exercises, development of nanotechnology & drug delivery systems, and development in transfection technologies such as nucleofection and magnetofection.
The Asia Pacific is expected to grow at the fastest CAGR over the forecast period. An increasing number of patients and the resulting market potential, combined with rising healthcare spending, are predicted to offer a beneficial opportunity for established global companies seeking to grow their operations in transfection reagents and equipment in the region.
Based on the product, the reagents segment dominated the transfection reagents and equipment market, with the largest revenue share of 53.1% in 2025. The segment is anticipated to dominate in the forecast period due to many launches by major players looking to expand their range of reagents.
The electroporation segment dominated the market in 2025. The broad selection of electroporation solutions from well-known and up-and-coming companies is driving growth in the segment.
The expanding commercialization of cell and gene therapies is creating significant growth opportunities for the transfection reagents and equipment market. Increasing investments in viral vector production, nucleic acid therapeutics, and advanced biologics manufacturing are driving demand for transfection technologies that support efficient gene delivery, manufacturing scalability, and consistent product quality.
North America dominated the Transfection Reagents & Equipment Market with the largest revenue share of 38.2% in 2025. This is attributable to the presence of well-established biopharmaceutical and genomic industries in the region.
The global transfection reagents & equipment market was estimated at USD 1.6 billion in 2025 and is expected to reach USD 1.7 billion in 2026.
The global transfection reagents & equipment market is expected to grow at a compound annual growth rate of 8.9% from 2026 to 2023 to reach USD 3.1 billion by 2033.
About the Author(s)
Biotechnology Research Team
Healthcare · BiotechnologyThis report was authored by the biotechnology research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the biotechnology segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
